An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Basil T DarrasMichelle A FarrarEugenio MercuriRichard S FinkelRichard FosterSteven G HughesIshir BhanWildon FarwellSarah GheuensPublished in: CNS drugs (2020)
NCT01494701, NCT01703988, NCT01839656, NCT02193074, NCT02292537, NCT01780246, NCT02052791.